Research Center Profile:
ICON Development Solutions - Manchester
Rachel Rossiter or Kimberley SpinksICON Development Solutions - ManchesterSkelton House, Manchester Science Park, Lloyd Street NorthManchester M15 6SHUnited Kingdom(315) 768-2500(315) 736-2460 (fax)IDSinfo@iconplc.comWebsiteContact Center
Infections and Infectious Diseases
Nutrition and Weight Loss
Trauma (Emergency, Injury, Surgery)
ICON’s hospital-based Clinical Pharmacology Unit in Manchester, UK has conducted clinical pharmacology studies for over 27 years. The newly constructed, state-of-the-art 52-bed facility on the Central Manchester University Hospital Foundation Trust (CMFT) campus and fully integrated into the Manchester Royal Infirmary (MRI) is suited to conduct studies in all major therapeutic areas. ICON has new dedicated ward in the Manchester Royal Infirmary Hospital that enables ICON to conduct a wide range of validated early-phase metabolic techniquesincluding Glucose Clamp Procedures, Graded Glucose Infusion, Glucose Tolerance Testing, Insulin Tolerance Testing, Maximum Stimulation Testing, as well as safety assessments of diabetic molecules, including Flow Mediated Dilation, Electrophysiology, Contractility and Platelet Aggregation.
ICON will be further expanding on the same hospital campus into a 40,000 square foot facility at Citylabs, a newly developed biomedical centre of excellence scheduled to open Q2 2014.
ICON’s partnership with the MRI provides full access to critical care facilities, including hospital emergency services, resuscitation team response, critical care beds and designated consultant level referral making this unit ideal for conducting first-in-human studies. Our collaborative relationship with the CMFT and the Manchester Academic Health Science Centre unrivalled access to the expertise, specialist procedures and patient populations.
Clinical Trials Experience
ICON Development Solutions has a wealth of experience of clinical pharmacodynamics. Current models at our Manchester facility include:
The Manchester unit is located at the Central Manchester University Hospital Foundation Trust (CMFT) campus and is fully integrated into the Manchester Royal Infirmary (MRI). The partnership with the MRI provides full access to critical care facilities making this unit ideal for conducting first-in-human studies.
The Manchester CPU medical team includes licensed physicians, nurses and phlebotomists. ICON enhances the medical expertise of its staff by providing regular training for medical and emergency care, and all medical staff maintains the necessary continuing education for compliance with their licensure and/or registration requirements.
Manchester employs 3 dedicated full-time Principal Investigators:
Peter Dewland, BSc, MA, MBBS, FFPM, DCPSA
Dr Simon Singer
Senior Clinical Research Physician/Principal Investigator
Dr. Pui Man “Paul” Leung
Senior Research Physician
Dr Karen BengEe So
Clinical Research Physician/Sub-Investigator
Manchester Leadership Team includes:
Dr Cyril Clarke, Vice President Translational Medicine
Dr John Connell, Vice President Pharmacodynamics
Gwen Aston, Site Head & General Manager
ICON Development Solutions’ Manchester Clinical Unit maintains an active database of over 10,000 volunteers which includes healthy male and female volunteers, non-child bearing females, genotyped males and females, “healthy elderlies” and patients with COPD and asthma. The main demographic is healthy, male, Caucasian aged 18-55, BMI 18 - 28, non smokers. The database is considered active (defined as having joined, screened or taken part in a study in the last 2 years) and clean, as the volunteers are contacted regularly (generally monthly) to ensure their interest is current.
If you are interested in contacting this center to discuss placing a clinical
trial there, please complete and send the email form below. A representative from
the research center will then follow up with you.
Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.
The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.
© Copyright 2000-2009 Multiple Sclerosis Foundation - All Rights Reserved